Skip to content
Larnaca, Cyprus
BINA CYINNOVATION HUBLarnaca · est. 2026
+Health20 November 20266 min read

Rare Disease Firsts, a Leukemia Vaccine Win, and World AMR Alarm

FDA approves a first brain drug for Gaucher disease; a leukemia vaccine shows Phase 3 survival gains; WHO sounds an AMR alarm.

By Dr. Asher Knippel

This week's roundup covers a rare-disease landmark, a promising new weapon against leukemia, two oncology approvals, evidence that lifestyle changes protect aging minds, and a global alert about the antibiotics we may no longer be able to rely on.

Wednesday, 18 November: FDA Approves First Drug for the Brain Symptoms of Type 3 Gaucher Disease

For decades, the thousands of patients living with Type 3 Gaucher disease — a rare inherited disorder in which a faulty enzyme allows fatty substances to accumulate inside cells — had no approved option for the most feared complication: progressive neurological damage. That changed on Wednesday when the U.S. Food and Drug Administration approved Infilbray (venglustat), a small-molecule substrate reduction therapy developed by Sanofi's Genzyme unit, specifically to treat the neurological symptoms of GD3 in adults and children weighing at least 15 kilograms.

The approval rested on a randomised, double-blind, Phase 3 trial that enrolled 43 patients aged 12 and older — a small but carefully assembled cohort for a disease so rare that large trial numbers are impractical. The FDA granted Infilbray both Orphan Drug Designation and Priority Review, reflecting an unmet need recognised across regulators. Enzyme replacement therapies such as Sanofi's Cerezyme, expanded for some non-neurological GD3 symptoms in January 2026, could address organ manifestations but had no demonstrated effect on the brain. Venglustat works differently: by reducing the production of the substrate that accumulates, it crosses the blood–brain barrier and reaches the cells where the damage occurs. MedCity News reported that the label carries a platelet-count warning and a mood-effect caution — signals to monitor as the drug enters broader use. Regulatory applications are under review in Europe and Japan.

Tuesday, 17 November: Leukemia Vaccine Extends Survival in Phase 3 — With Important Caveats

A cancer vaccine that trains the immune system to recognise and attack leukaemia cells has cleared a major milestone. SELLAS Life Sciences announced topline results from the Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukaemia: the vaccine reduced the risk of death by 41% compared with best available therapy (hazard ratio 0.59, two-sided p = 0.035), extending median overall survival from 14.7 months to 24.0 months. The trial enrolled 126 patients who had reached a second or later complete remission after relapsed or refractory disease but could not proceed to a stem cell transplant.

Galinpepimut-S targets the Wilms' Tumour 1 (WT1) protein, which is overexpressed on many leukaemia cells, stimulating T-cell responses that aim to keep residual disease in check during remission. If those results hold under regulatory scrutiny, it could represent the first immunotherapy approved in this AML maintenance setting. Several important caveats apply. The results are company-reported topline data; the full dataset has not been peer-reviewed or published. TechTimes noted that no confidence interval accompanied the announced hazard ratio, and CancerNetwork confirmed that the analysis plan was modified in 2022 before unblinding — a detail independent statisticians will want to scrutinise carefully. SELLAS plans to submit a Biologics License Application to the FDA; a regulatory timeline has not been confirmed.

Monday, 16 November: Roche's Wilserdly Becomes the Fourth Oral SERD Approved for Advanced Breast Cancer

Hormone receptor-positive breast cancer that acquires mutations in the ESR1 gene — which codes for the oestrogen receptor — often develops resistance to standard hormonal therapies. Roche's Wilserdly (giredestrant) entered the medicine cabinet on Monday as the FDA approved it in combination with everolimus for adults with oestrogen receptor-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, making it the fourth oral selective estrogen receptor degrader (SERD) to reach U.S. patients.

The approval arrived alongside a companion blood test from Roche's diagnostics arm that identifies the ESR1 mutation in circulating tumour DNA — allowing clinicians to select patients most likely to benefit without requiring a fresh tissue biopsy. Efficacy data showed that the combination delayed cancer progression by a median of 4.5 months longer than an older standard regimen; overall survival data are still immature. FiercePharma and BioPharma Dive noted that a separate filing for early-stage adjuvant use, based on the lidERA trial, is under Priority Review with an FDA target action date of 30 November 2026.

Wednesday, 18 November: Structured Lifestyle Programme Protects the Ageing Brain, U.S. POINTER Trial Reports

New data from the U.S. POINTER trial — the largest multisite lifestyle intervention trial for brain health conducted in the United States — delivered a hopeful message at the Clinical Trials on Alzheimer's Disease (CTAD) 2026 conference in Boston: improving cardiometabolic health measurably improves cognition. The 2,111-person trial enrolled adults aged 60 to 79 with a sedentary lifestyle and elevated dementia risk, comparing a structured programme (personalised exercise, dietary counselling, cognitive training, and cardiovascular risk management) with a self-guided healthy lifestyle programme over two years.

The CTAD 2026 analysis found that participants in the structured arm showed greater improvements in body mass index, waist circumference, diastolic blood pressure, resting heart rate, cholesterol, triglycerides, and blood sugar than those following the self-guided programme — and that these cardiometabolic gains were directly linked to better performance on cognitive tests. The Alzheimer's Association reported that the benefit held consistently for men and women, for participants younger and older than 70, and regardless of APOE4 carrier status, the genetic variant that roughly triples Alzheimer's risk. UC Davis Health, one of the trial sites, noted the results reinforce what cardiologists have long suspected: the same habits that protect the heart protect the brain. The main POINTER trial paper, published in JAMA in July 2025, showed the structured programme improved global cognition; the new CTAD analyses illuminate the cardiometabolic mechanism by which those cognitive gains occur. For health systems concerned about dementia prevention, the practical message is straightforward: regular exercise, dietary improvement, and blood-pressure control are among the most evidence-grounded brain-protective interventions available today.

Tuesday–Friday, 18–24 November: WHO and ECDC Sound the Alarm as World AMR Awareness Week Opens

World Antimicrobial Resistance Awareness Week runs from 18 to 24 November 2026 under the theme One Health, One Action: Prevent AMR Now. This year's opening was accompanied by a sobering joint alert from the World Health Organization and the European Centre for Disease Prevention and Control, warning that antimicrobial resistance in healthcare settings is advancing faster than national response plans in most of the world.

WHO's survey of 183 countries found that only 36% possess a national reference laboratory capable of testing resistance across all monitored bacteria and fungi — against a global target of 80% by 2030. Without reliable resistance data, clinicians are, in a WHO official's words, left to treat patients without knowing the pathogen or which antibiotic will work. UN News reported that WHO and ECDC jointly highlighted resistant bacteria in hospital settings as a critical concern, and that 16 of 51 analysed countries still lack a standardised national approach to surveillance and coordination.

The implications are tangible for the eastern Mediterranean region, where antibiotic use in both human medicine and agriculture has historically been high, and where primary-care infrastructure varies widely across borders. AMR does not respect geography: a drug-resistant pathogen that exhausts treatment options in a Nicosia intensive care unit or a Beirut hospital is a problem for every patient in the region. AMR Awareness Week provides an annual moment for health ministries, prescribers, and patients to recall that every unnecessary antibiotic prescription draws against a shared and finite resource.


The content in this article is journalistic reporting and does not constitute medical advice. Readers are encouraged to consult a qualified clinician before making any change to a treatment, medication, or health management plan.